Over a quarter of T2DM patients with hypertension/high-normal BP eligible for SGLT2i/GLP1-RA were at risk of cardiac damage (even subclinical) according to NT-proBNP levels. Most would receive an indication for an echocardiogram and specialist referral, allowing early implementation of strategies to prevent/delay progression to advanced cardiac disease and overt HF. BP burden and renal damage were the most relevant risk factors. This evidence concerns the gene GLP1R and hypertensive disorder.